SCHEMBL5363358

SCHEMBL5363358

CCOP(=O)(OCC)C(N(Cc1ccccc1)c1ccccn1)P(=O)(OCC)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.43
POLB P06746 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
CHRM2 P08172 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
DRD1 P21728 1/20 0.43
SLC6A2 P23975 1/20 0.43
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
ADRA1A P35348 1/20 0.43
HRH1 P35367 1/20 0.43
OPRK1 P41145 1/20 0.43
SLC6A3 Q01959 1/20 0.43
KCNH2 Q12809 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361049 0.89 LMNA (0.50) ALDH1A1GAAPOLBSMN1; SMN2CHRM2
SCHEMBL5359433 0.81 POLB (0.37) ALDH1A1POLBKCNH2LMNACYP1A2
SCHEMBL5361045 0.81 ALDH1A1 (0.43) ALDH1A1GAAPOLBSMN1; SMN2CHRM2
SCHEMBL5363670 0.80 POLB (0.43) ALDH1A1GAAPOLBSMN1; SMN2TSHR
SCHEMBL5007472 0.78 ALDH1A1 (0.49) ALDH1A1GAAPOLBADRA2BADRA2C
SCHEMBL1848683 0.76 POLB (0.50) ALDH1A1GAAPOLBSMN1; SMN2KCNH2
SCHEMBL7844346 0.74 TAAR1 (0.58) ALDH1A1GAAPOLBSMN1; SMN2CHRM2
SCHEMBL12876278 0.74 LMNA (0.46) ALDH1A1GAAPOLBADRA2BADRA2C
SCHEMBL11700180 0.72 ALDH1A1 (0.51) ALDH1A1GAAPOLBSMN1; SMN2CHRM2
SCHEMBL9232148 0.71 POLB (0.49) ALDH1A1GAAPOLBSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208481-B2 Aminodiphosphonate apolipoprotein E modulators ILEX PRODUCTS, INC. (US) 2007-04-24 US claimed
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators PHAN HIEU TRUNG (CH) 2005-04-07 US claimed
EP-1482897-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS Ilex Products, Inc. (US) 2004-12-08 EP claimed
WO-2003070169-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS ILEX PRODUCTS, INC. (US) 2003-08-28 WO claimed
US-7208481-B2 Aminodiphosphonate apolipoprotein E modulators ILEX PRODUCTS, INC. (US) 2007-04-24 US disclosed
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators PHAN HIEU TRUNG (CH) 2005-04-07 US disclosed
EP-1482897-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS Ilex Products, Inc. (US) 2004-12-08 EP disclosed
WO-2003070169-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS ILEX PRODUCTS, INC. (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators APOB, APOL1, NAPEPLD ALDH1A1 3096/4885GAA 2384/4885POLB 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.